Johnson & Johnson (JNJ) agreed to acquire Intra-Cellular Therapies (ITCI), a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on "Bloomberg Open Interest."

Bloomberg videos, provided by MT Newswires